AMENDMENT No. 1 to the FACILITY USE AGREEMENTFacility Use Agreement • August 12th, 2019 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment No. 1 to the Facility Use Agreement (the “Agreement”) (hereinafter referred to as the “Amendment”) is made as of April 17, 2019 (the “Effective Date”), by and between the INSTITUTE FOR SYSTEMS BIOLOGY (“ISB”), a Washington non-profit corporation, and NEOLEUKIN (“User”), a Delaware Corporation. ISB and the Company are collectively referred to as the “Parties” and individually as a “Party”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN...Exclusive Start-Up License Agreement • August 12th, 2019 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • Washington
This Exclusive License Agreement (this “Agreement”), effective as of the date of last signature (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Neoleukin Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Company”).
FACILITY USE AGREEMENTFacility Use Agreement • August 12th, 2019 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • Washington
This Facility Use Agreement (the “Agreement”) is entered into as of December 4,2018 (the “Effective Date”), by and between the Institute for Systems Biology (“ISB”), a non-profit Washington corporation, and Neoleukin a Delaware corporation (the “User”) (both collectively referred to as the “Parties” and individually as a “Party”).
